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SUMMARY
There is evidence that an early start of penicillin reduces the case-fatality rate of leptospirosis and that chemoprophylaxis is
efficacious in persons exposed to the sources of leptospira. The existent data, however, are inconsistent regarding the benefit of
introducing penicillin at a late stage of leptospirosis. The present study was developed to assess whether the introduction of penicillin
after more than four days of symptoms reduces the in-hospital case-fatality rate of leptospirosis. A total of 253 patients aged 15 to 76
years with advanced leptospirosis, i.e., more than four days of symptoms, admitted to an infectious disease hospital located in
Salvador, Brazil, were selected for the study. The patients were randomized to one of two treatment groups: with intravenous penicillin,
6 million units day (one million unit every four hours) for seven days (n = 125) and without (n = 128) penicillin. The main outcome
was death during hospitalization. The case-fatality rate was approximately twice as high in the group treated with penicillin (12%; 15/
125) than in the comparison group (6.3%; 8/128). This difference pointed in the opposite direction of the study hypothesis, but was
not statistically significant (p = 0.112). Length of hospital stay was similar between the treatment groups. According to the results of
the present randomized clinical trial initiation of penicillin in patients with severe forms of leptospirosis after at least four days of
symptomatic leptospirosis is not beneficial. Therefore, more attention should be directed to prevention and earlier initiation of the
treatment of leptospirosis.
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INTRODUCTION
Leptospirosis is a worldwide zoonotic disease caused by Leptospira
interrogans10,14,15,18. The severe cases are characterized by a high frequency
of jaundice, acute renal failure, bleeding complications, heart failure,
cardiac arrhythmias and respiratory failure6,10,17,19,20,22. In Salvador, a large
city located in the state of Bahia in Northeast Brazil, the disease is endemic
with outbreaks occurring in close relation to the increase in the
pluviometric precipitation4,5,16. The in-hospital case-fatality rate of
leptospirosis in Salvador is approximately 12%25. This high death rate
may be partly explained by the high frequency of severe disease among
patients hospitalized with leptospirosis in Salvador16,17. The highest
mortality risk has been described among patients who need mechanical
ventilation or develop oliguric acute renal failure19,23. An increased
mortality risk may also be due to a delay to start treatment3.
BULMER reported in 1945 the first study about the effect of
penicillin in patients with leptospirosis3. The benefit of the treatment
was observed only when penicillin was introduced at an early stage of
the disease. Other studies have failed to demonstrate benefit of penicillin
in leptospirosis8,15. It is not clear, however, the influence of the stage of
the disease on these negative results. Similar to BULMER3, MCCLAIN
et al.21 showed evidence of a beneficial effect of the introduction of an
antibiotic (doxycycline) at early stages of the leptospirosis. There is also
evidence that doxycycline may prevent leptospirosis in highly exposed
populations26. WATT et al., in a randomized, double-blinded clinical
trial among patients with predominantly advanced leptospirosis, showed
a smaller duration of hospital stay and fever in patients treated with
penicillin28. In this study by WATT et al., however, it was not possible to
assess the effect of penicillin on the case-fatality rate because there was
no death case, both in the penicillin and the placebo groups. The present
study was developed in Salvador specifically to assess whether the
introduction of penicillin after at least four days of symptoms reduces
the case-fatality rate of leptospirosis.
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METHODS
From August 1997 to July 1999, 253 patients admitted to Couto
Maia Hospital, an infectious disease hospital located in Salvador-BA,
were selected for the present study. Each patient signed a consent form,
approved by the local institutional review board and was randomly
assigned to be treated with (n = 125 patients) or without penicillin (n =
128) at a dose of 6 million units day (one million unit every four hours)
for seven days. To be eligible for randomization the patient had to have
more than four days of symptoms (i.e., late stage) and reach at least 26
points in the World Health Organization (WHO) probability score for
leptospirosis9. The score was based on six clinical findings (headache,
fever, conjunctival suffusion in both eyes, meningeal signs, myalgia and
jaundice), azotemia and evidence of exposure to sources of leptospira
(i.e., rats or contaminated water). In addition, the macroscopic slide test,
the microagglutination test (MAT) and blood culture were performed
for laboratory confirmation of leptospirosis. Exclusion criteria were: age
below 15 years, history of allergy to penicillin, immunodeficiency,
previous history of nephropathy or cardiomyopathy, diabetes mellitus
and pregnancy.
The patients were submitted to a list of laboratory exams at hospital
admission that were repeated at least in the days 3 ± 1 and 7 ± 1 after
admission. The list consisted of hemogram, bilirubins, aminotransferases
(AST, ALT), prothrombin time, urea, creatinine, sodium, potassium,
albumin, urinalysis and serologic tests for leptospirosis. The blood sample
for bacteriological identification of leptospira was collected at admission.
The MAT and blood culture for leptospira were performed at Centro de
Pesquisas Gonçalo Moniz da Fundação Oswaldo Cruz/FIOCRUZ. The
macroscopic slide test was performed at the Laboratório Central de Saúde
Pública Gonçalo Moniz/LACEN. The MAT was considered positive
when there was at least four-fold increase in the reciprocal titre between
paired serum samples or when the reciprocal titre was greater than 800
in one or more serum samples. The MAT was defined as probable when
the reciprocal titre was between 100 and 800. For 127 patients chest
radiographs were performed independently of clinical manifestations.
The radiographs were independently analyzed by two pneumologists
who were blinded to any other data of the patients. The inter-observer
agreement between the pneumologists was high (kappa = 0.7).
Radiographs with discordant diagnoses were submitted to a radiologist
for independent opinion. The discordance was resolved by consensus
among the three observers.
Statistical Analysis. Intention to treat analysis was used. The t test
and chi-square test for independent groups were used to compare
differences in quantitative and qualitative variables, respectively. Logistic
regression was used to adjust the association between treatment (groups
with and without penicillin) and death rate for base-line difference in
the leukocyte count. To obtain adjusted odds ratio, two dummy variables
were defined for leukocyte count: 10,001 to 20,000 per mm3 and 20,001-
plus. Leukocyte count ≤ 10,000 was used as the referent.
RESULTS
The macroscopic slide test was performed for 252 of 253 patients,
being positive in 247. The MAT was performed for 65 patients being
positive for 45 and probable for 8. Positive hemocultures were found in
17 out of 21 patients. In one patient the diagnosis was based only in
clinical and epidemiological findings.
Table 1 shows the baseline characteristics of the patients. Icterus at
hospital admission was present in 94.1% (238/253). The penicillin and
Table 1
Baseline characteristics of the patients
Penicillin Control
Characteristic N = 125 N = 128 p value
Male, n/N (%) 110/125(88.0) 117/128(91.4) 0.372
Icteric, n/N (%) 118/125(94.4) 120/128(93.8) 0.827
Altered chest radiograph at admission, n/N (%) 16/61(26.2) 17/66(25.8) 0.952
Shortness of breath 4/125(2.2) 8/128(6.3) 0.254
Creatinine ≥ 1.5 mg/dl, n/N (%) 112/122(91.8) 116/127(91.3) 0.895
Creatinine > 3.0 mg/dl, n/N (%) 40/122(32.8) 35/127(27.6) 0.369
Bleeding* 39/117(33.3) 39/124(31.5) 0.755
Age in years, mean ± SD (N) 35.8 ± 13.9(125) 35.1 ± 13.1(128) 0.700
Duration of symptoms in days, mean ± SD (N) 6.6 ± 1.8(125) 6.5 ± 1.6(128) 0.349
Body temperature in Celsius scale, mean ± SD (N) 37.0 ± 0.9(118) 37.0 ± 0.7(120) 0.546
Hematocrit, mean ± SD (N) 34.0 ± 5.5(116) 34.5 ± 5.0(124) 0.483
Leucocyte count, mean ± SD (N) 16325 ± 6436(120) 14584 ± 4594(125) 0.016
Total bilirubin in mg/dl, mean ± SD (N) 20.7 ± 11.9(113) 22.2 ± 14.4(113) 0.370
Creatinine in mg/dl, mean ± SD (N) 4.6 ± 2.3(123) 4.3 ± 2.0(127) 0.398
Sodium in mEq/l, mean ± SD (N) 134.0 ± 6.5(100) 132.2 ± 5.8(92) 0.354
Potassium in mEq/l, mean ± SD (N) 3.4 ± 0.7(102) 3.4 ± 0.7(98) 0.673
Albumin in g/dl, mean ± SD (N) 3.0 ± 0.5(95) 3.0 ± 0.6(107) 0.764
* the source of bleeding was identified as respiratory or gastrointestinal in 96.2% of the cases
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the control groups were similar regarding the presence of jaundice,
gender, age, duration of the disease and body temperature. Laboratory
findings at admission were similar between the groups, except for the
leukocyte count (higher in the penicillin group). All laboratory exams
performed around the 3rd and the 7th hospitalization days were similar
between the penicillin and the control groups (the data are not shown in
the table). Renal failure at admission, defined as serum creatinine ≥ 1.5
mg/dL, was observed for 91.6% of the patients. The percent of patients
with renal failure was similar between the penicillin (91.8%) and the
control (91.3%) groups. Creatinine > 3.0 mg/dL at admission was present
in approximately 32.8% and 27.6% of the patients randomized to the
penicillin and control groups, respectively (p = 0.369). Significant
differences were also not observed between the penicillin and the control
groups regarding the percentages of patients with shortness of breath
and bleeding at hospital admission. Among 127 patients who had a chest
radiograph performed, independently of the clinical manifestations,
radiological alterations were detected in 33 (26%). The percentage of
radiographs with alterations was similar between patients of the penicillin
(26.3%) and the control (25.8%) groups. Alveolar infiltrate was the
predominant radiologic pattern being observed in 12 of the 16 radiographs
with alterations in the penicillin group and in 12 of the 17 in the control
group.
There were 23 cases of death. These deaths were attributed to acute
renal failure, respiratory failure and multiple organ failure in 14 (60.9%),
1 (4.3%) and 8 (34.8%) patients, respectively. Approximately 44% of
the death cases occurred within the first three days of hospitalization.
These early deaths corresponded to 46.7% (7/15) and 35.7% (3/8) of the
fatal cases in the groups penicillin and control, respectively. The in-
hospital case-fatality rate (Table 2) was higher in the penicillin group
(12.0%; 15/125) than in the control group (6.3%; 8/128); the difference,
however, was not statistically significant (p = 0.112). The odds of death
remained higher in the penicillin than in the control group, even after
taking into account baseline difference in the leukocyte count (odds ratio
= 1.94, 95% confidence interval = 0.78-4.80). All deaths were observed
among icteric patients. The length of hospital stay was similar between
the penicillin (8.9 ± 3.9 days) and the control (8.8 ± 3.6 days) groups
(the data are not shown in the table). In an analysis restricted to patients
who remained alive during hospitalization, there was also no important
difference between the groups in the length of hospital stay; 9.4 ± 3.5
and 9.0 ± 3.4 days for the penicillin and the control groups, respectively.
Peritoneal dialysis was the modality of renal replacement therapy for
acute renal failure. It was used for 28% (35/125) of the patients in the
penicillin group and 18% (23/128) in the control group (p = 0.058).
DISCUSSION
The results of the present work do not support the idea that penicillin
has a beneficial effect in patients with leptospirosis when it is started
after the fourth day of the disease. Although the difference was not
statistically significant, the case-fatality rate was greater in the group
randomized to penicillin. In addition, the hospital stay was similar
between the groups. It is also important to note that according to the
reports from the Health Secretary of Bahia relative to the period 1988-
1999, the in-hospital case-fatality rate of leptospirosis in Salvador is
around 12 percent25. This case-fatality rate is similar to that found in the
group treated with penicillin in the present study and superior to the one
observed in the control group.
To our knowledge the only randomized clinical trial that reported
benefit with penicillin when the treatment was started late in the course
of the disease was the study by WATT et al.28. In order to compare our
results with those reported by WATT et al., however, it is important to
take into account the severity of the disease and the outcome used to
assess treatment efficacy. In the study by WATT et al., only half of the
sample had elevated levels of bilirubin and icterus by physical
examination was reported for approximately 45%. By contrast, in the
present study more than 90 percent of the patients were icteric. WATT et
al. observed a shorter duration of fever and hospital stay among the
patients on penicillin than among those from the control group. None of
the patients died, what is consistent with the fact that the group was
comprised of patients with less severe forms of leptospirosis as compared
to the present study. Since there was no fatal case, it is not possible to
conclude by this previous study whether the introduction of penicillin at
late stage of leptospirosis is related to reduction in the case-fatality rate.
In the trial by WATT et al., and in other previous studies, the use of
antibiotics was also associated with a faster disappearance of the
leptospiruria2,8,21,28. There is no evidence, however, that this finding is
associated with a better prognosis of the disease.
Even though in the present study the treating physicians were not
blind to the patient assignment, the fact that the main outcome (death) was
a very objective one reduces the possibility of bias. Our data suggesting
that penicillin do not reduce the probability of death when it is introduced
late in the course of leptospirosis provide additional support to the
importance of an earlier start of the antimicrobial treatment in suspect
cases. In addition, the use of penicillin did not decrease the need for dialysis
treatment. In fact there was a tendency for a higher frequency of patients
who needed dialysis in the penicillin group. DAHER & NOGUEIRA
studied a sample of 43 patients from the state of Ceará with acute renal
failure due to leptospirose and a high mean duration of symptoms and
have also not found a beneficial effect of penicillin in preventing adverse
outcomes7. Experimental investigations in animals and human studies have
shown evidence that the use of antimicrobial agents soon after the
appearance of symptoms improves the prognosis of leptospirosis2,21. In
addition, there is evidence favoring the use of antibiotics in persons exposed
to the sources of leptospira13,24,26. These findings are consistent with the
idea that once established the tissue lesions by the leptospira the antibiotic
cannot change the course of the disease.
The present sample was comprised of patients with severe forms
and late stage of leptospirosis. Therefore, our results cannot be generalized
Table 2
Unadjusted and logistic-regression adjusted associations between
demographic characteristics and in-hospital case-fatality rate
Death Odds ratios (95% CI)
Treatment group Yes No % death Unadjusted Adjusted*
Penicillin 15 110 12.0 2.04 1.94
(0.83-5.01)φ (0.78-4.80)↑
Control 8 120 6.3 referent referent
*odds ratio adjusted for leukocyte count at admission; φp = 0.118; ↑p = 0.154
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to the whole population of patients with this disease. It is important to
note that approximately 44% of the deaths occurred within the first three
days of hospitalization with a slight preponderance of early death among
patients randomized to penicillin. It is plausible to hypothesize that
because of the severity of the disease some patients randomized to
penicillin died before receiving the benefit of the treatment. There is
also the possibility that the clinical manifestation of leptospirosis worse
after the initiation of antibiotic therapy due to the development of Jarisch-
Herxheimer reaction27. However, in the present study we have not
observed classical manifestations of Jarisch-Herxheimer in none of the
patients treated by penicillin.
In conclusion, the results of the present randomized clinical trial in
patients with severe forms of leptospirosis do not support the hypothesis
that the initiation of penicillin after at least four days of symptomatic
disease is beneficial. Our data call attention to the need for a greater
emphasis on the prevention of leptospirosis and identification of patients
with symptomatic disease at an earlier stage when the initiation of
antibiotic therapy seems to be efficacious in decreasing the risk of death.
RESUMO
Penicilina na fase avançada da leptospirose: um ensaio clínico
randomizado
Existe evidência de que o início precoce do tratamento com penicilina
reduz a letalidade da leptospirose e de que a quimioprofilaxia é eficaz
em pessoas expostas às fontes de infecção. Os dados existentes, contudo,
são inconsistentes quanto ao benefício de iniciar penicilina na fase tardia
da leptospirose. O presente estudo foi desenvolvido para avaliar se a
introdução de penicilina após mais de quatro dias de sintomas reduz a
letalidade da leptospirose. Um total de 253 pacientes entre 15 e 76 anos
de idade, com leptospirose avançada, i.e., mais de quatro dias de sintomas,
admitidos em um hospital de doenças infecciosas localizado em Salvador,
Brasil, foram selecionados para o estudo. Os pacientes foram
randomizados para um dos seguintes grupos de tratamento: com
penicilina intravenosa, 6 milhões de unidades/dia (um milhão de unidades
cada quatro horas) por 7 dias (n = 125) e sem penicilina (n = 128). O
evento principal foi morte durante o período de internamento. A letalidade
foi aproximadamente duas vezes maior no grupo tratado com penicilina
(12%; 15/125) do que no grupo de comparação (6,3%; 8/128). Esta
diferença seguiu direção oposta a da hipótese do estudo, porém não
alcançou significância estatística (p = 0,112). A duração do internamento
foi similar entre os grupos de tratamento. De acordo com os resultados
do presente ensaio clínico randomizado o uso de penicilina não é benéfico
em paciente com leptospirose quando iniciado com pelo menos quatro
dias após o início dos sintomas. Portanto, maior atenção deve ser dada à
prevenção e ao inicio mais precoce do tratamento da leptospirose.
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